**Core Concept**
The question aims to test the knowledge of pharmacological interventions for nicotine addiction. Nicotine addiction is a complex condition that involves the brain's reward system, and management typically involves non-pharmacological and pharmacological approaches. The correct answer is a medication that has been approved for the treatment of nicotine dependence.

**Why the Correct Answer is Right**
The correct answer is **Varenicline**. Varenicline is a partial agonist at the α4β2 nicotinic acetylcholine receptor, which is the primary receptor subtype involved in nicotine addiction. By activating this receptor, varenicline reduces the pleasurable effects of smoking and decreases the urge to smoke. Additionally, varenicline blocks the action of nicotine at the α4β2 receptor, further reducing the reinforcing effects of smoking.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because bupropion is a medication primarily used for the treatment of depression and seasonal affective disorder. While it is sometimes used off-label for smoking cessation, it is not the primary pharmacological agent for nicotine addiction prophylaxis.
* **Option B:** This option is incorrect because nortriptyline is a tricyclic antidepressant that has been used for smoking cessation, but it is not the preferred or primary medication for nicotine addiction prophylaxis.
* **Option C:** This option is incorrect because clonidine is an alpha-2 adrenergic agonist used primarily for the treatment of hypertension and ADHD. It has been studied as a potential treatment for nicotine addiction, but it is not the standard or preferred medication for this indication.

**Clinical Pearl / High-Yield Fact**
Varenicline is a medication that works by targeting the brain's reward system, specifically the α4β2 nicotinic acetylcholine receptor. This mechanism of action allows it to reduce the pleasurable effects of smoking and decrease the urge to smoke.

**Correct Answer:** C. Varenicline